
Omada Health, Inc.: stock overview
Price
$14.33
November 13, 2026Market cap $889M
What Ploutos Investor adds for Omada Health
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
In short
Omada Health had revenue of $333M over the last 12 months and net income of $14M, a net margin of 4.2%. Revenue grew by 45.6% a year on average over the last 2 years. At $14.33 the shares trade at a P/E of 63.4. It holds more cash than debt, by $243M. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $889M
- 62.04M shares
- P/E
- 63.4
- Revenue, 12 months
- $333M
- +45.6% a year over 2 years
- Net margin
- 4.2%
- 2025: -4.9%, above 39% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+45.6% a year over 2 years
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap
- $889M
- Enterprise value
- $646M
- P/E
- 63.4
- EV / EBIT
- 94.0
- EV / Revenue
- 1.9
- P/B
- 3.3
- FCF yield
- 3.2%
- Earnings yield
- 1.6%
Profitability
- Gross margin
- 70.7%
- Operating margin
- 2.1%
- Net margin 3-year median: -27.8%
- 4.2%
- ROIC
- 2.3%
- ROIC, 5-year average
- -4.1%
- ROE
- 5.8%
Growth
- Revenue, yearly change
- +53.2%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +45.6%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $243M
- Total debt
- $0
- Net cash
- $243M
- Net debt / EBITDA
- -19.7x
- Interest cover
- 22.4x
- Current ratio
- 4.18
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +622.4%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 80).
Gross margin
65.7%
Above 66% of the 25 companies in its industry, and 83% of all.
Operating margin
-4.6%
Above 35% of the 62 companies in its industry, and 26% of all.
Net margin
-4.9%
Above 39% of the 68 companies in its industry, and 24% of all.
ROE
-5.6%
Above 34% of the 58 companies in its industry, and 23% of all.
ROA
-4.2%
Above 31% of the 69 companies in its industry, and 22% of all.
Revenue growth
53.2%
Above 95% of the 68 companies in its industry, and 95% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Omada Health, Inc.
- CIK
- 1611115
- Exchange
- NASDAQ
- Industry (SIC)
- 8000 · Services-Health Services
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 62.04M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with OMDA
- JNJJohnson & Johnson+0,00%Compare with OMDA
- ABBVAbbVie+0,00%Compare with OMDA
- UNHUnitedHealth+0,00%Compare with OMDA
- MRKMerck & Company+0,00%Compare with OMDA
- AMGNAmgen+0,00%Compare with OMDA
- TMOThermo Fisher Scientific+0,00%Compare with OMDA
- ABTAbbott Laboratories+0,00%Compare with OMDA
The full analysis
What do Omada Health's filings show?
These are Omada Health's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is OMDA's market cap?
Omada Health, Inc.'s market cap is $889M, at a price of $14.33 on November 13, 2026 and 62.04M shares.
What is OMDA's P/E?
OMDA's P/E is 63.4, on earnings per share of $0.23 over the last 12 months.
How much revenue does OMDA have?
Omada Health had revenue of $333M over the last 12 months. Over the last 2 years it changed by +45.6% a year on average.
Does OMDA pay a dividend?
No. Omada Health paid no regular dividend over the last 12 months.
Where do the figures come from?
From Omada Health, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.